Tetrazole and ester substituted tetrahydoquinoxalines as potent cholesteryl ester transfer protein inhibitors

Bioorganic and Medicinal Chemistry Letters

Volumn 17, Issue 9, 2007, Pages 2608-2613

  Eary, C Todd ^a   Jones, Zachary S ^a   Groneberg, Robert D ^a   Burgess, Laurence E ^a   Mareska, David A ^a   Drew, Mark D ^a   Blake, James F ^a   Laird, Ellen R ^a   Balachari, Devan ^a   O'Sullivan, Michael ^a   Allen, Andrew ^a   Marsh, Vivienne ^a  

^a ARRAY BIOPHARMA INC   (United States)

Author keywords

CETP; Cholesterol; Cholesteryl ester transfer protein; HDL; Tetrahydoquinoxalines

Indexed keywords

CHOLESTEROL ESTER; CHOLESTEROL ESTER TRANSFER PROTEIN; ESTER DERIVATIVE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LIPOPROTEIN; PLASMA PROTEIN; QUINOXALINE DERIVATIVE; TETRAZOLE DERIVATIVE;

ARTICLE; CHOLESTEROL BLOOD LEVEL; DIASTEREOISOMER; DISTRIBUTION VOLUME; DRUG CLEARANCE; DRUG POTENCY; DRUG SYNTHESIS; ENANTIOMER; IC 50; IN VITRO STUDY; IN VIVO STUDY; NONHUMAN; STEREOCHEMISTRY; STRUCTURE ACTIVITY RELATION;

ANIMALS; CHEMISTRY, PHARMACEUTICAL; CHOLESTEROL ESTER TRANSFER PROTEINS; CHOLESTEROL, HDL; DRUG DESIGN; ESTERS; HUMANS; HYDROGEN-ION CONCENTRATION; INHIBITORY CONCENTRATION 50; MOLECULAR CONFORMATION; QUINOXALINES; RATS; STEREOISOMERISM; STRUCTURE-ACTIVITY RELATIONSHIP; TETRAZOLES;

EID: 33947718135     PISSN: 0960894X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bmcl.2007.01.112     Document Type: Article

References (18)

1. Vrecer M., Turk S., Drinovec J., and Mrhar A. Int. J. Clin. Pharmacol. Ther. 41 (2003) 567
2. Brewer Jr. H.B. N. Engl. J. Med. 350 (2004) 1491
3. Nicholls S.J., and Nissen S.E. Eur. Heart J. 26 (2005) 853
4. Ito M.K. Am. J. Manag. Care 8 (2002) S315
5. Inazu A., Brown M.L., Hesler C.B., Agellon L.B., Koizumi J., Takata K., Maruhama Y., Mabuchi H., and Tall A.R. N. Engl. J. Med. 323 (1990) 1234
6. Clark R.W., Sutfin T.A., Ruggeri R.B., Willauer A.T., Sugarman E.D., Magnus-Aryitey G., Cosgrove P.G., Sand T.M., Wester R.T., Williams J.A., Perlman M.E., and Bamberger M.J. Arterioscler. Thromb. Vasc. Biol. 24 (2004) 490
7. Shinkai H., Maeda K., Yamasaki T., Okamoto H., and Uchida I. J. Med. Chem. 43 (2000) 3566
8. Cao, G.; Escribano, A. M.; Fernandez, M. C.; Fields, T. Gernert, D. L.; Cioffi, C. L.; Herr, R. J.; Mantlo, N. B.; Martin De La Nava, E. M.; Mateo, Herranz, A. I.; Mayhugh, D. R.; Wang, X., WO05037796, 2005.
9. Sikorski J.A. J. Med. Chem. 49 (2006) 1
10. Gray B.D., and Jeffs P.W. J. Chem. Soc., Chem. Commun. (1987) 1329
11. Prepared from the esterification of commercially available 3,5-bis(trifluoromethyl) phenylacetic acid.
12. Aliphatic regio-substitution at N-1 versus N-4 was determined via NMR 1-D (one dimensional) NOESY (nuclear Overhauser enhancement spectroscopy) via soft shaped pulse excitation or 2-D gHMBC (gradient Heteronuclear Multiple Bond Correlation).
13. The structural assignment for 14 was based upon gHMBC NMR.
14. 3H-CE-HDL remaining.
15. Herr R.J. Bioorg. Med. Chem. 10 (2002) 3379
16. Alkylation of the tetrazole moiety produced a general trend with the N2 isomer as major accompanied with minor amounts of the N1 isomer (5-15%). The regiochemistry of compound 27 was determined through gHMBC NMR.
17. Still W.C., Kahn M., and Mitra A. J. Org. Chem. 43 (1978) 2923
18. These analogs were prepared as described in Scheme 4 utilizing optically active tetrahydroquinoxaline 6. The R and S tetrahydroquinoxaline cores were prepared as described in Scheme 1 utilizing commercially available (R)-(-)-2-amino-1-butanol and (S)-(+)-2-amino-1-butanol.